DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Roche - 3 we've - 2 Ludwig Burger - 2 It's - 1 MoonLake Immunotherapeutics - 1 Stifel - 1 Alex Thompson - 1 Thompson - 1
Top related locs:
Japan France Bellevue Lyon Paris Roivant Basel Switzerland
Top related orgs:
Sanofi - 3 Pfizer - 2 REUTERS - 2 Merck & Co - 2 Thomson - 2 Prometheus Biosciences - 2 pharma - 2 Bellevue Asset Management - 1

Search resuls for: "TL1a"


5 mentions found


☆ Stifel says this under-the-radar biotech stock can still rally more than 50% from here
  + stars: | 2023-11-02 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +1 min
It's not too late for investors to ride along with MoonLake Immunotherapeutics despite the Swiss biotech having more than quadrupled in price this year, according to Stifel. Shares of MoonLake have soared 354% in 2023, but Stifel believes more gains lay ahead. MLTX YTD mountain MLTX YTD chart Analyst Alex Thompson believes MoonLake's sonelokimab drug, which targets diseases in dermatology and rheumatology, could eventually achieve $4.2 billion in U.S. revenue. The next trial readout for the drug is in psoriatic arthritis, with data expected in early November. "We view recent acquisitions in the TYK2 and TL1A space ($4-11B) as supportive of Strategics' interest/willingness to pay premiums in these markets," Stifel noted.
Persons: It's, MoonLake Immunotherapeutics, Stifel, Alex Thompson, we've, Thompson, MoonLake, — CNBC's Michael Bloom
☆ Sanofi loses $21 bln in market value after dropping 2025 profit target
  + stars: | 2023-10-27 | by ( Ludwig Burger | ) www.reuters.com   time to read: +6 min
Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability". EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target. CONSUMER STAND-ALONECEO Hudson said the core innovative drugs business had improved enough to soon do without the more predictable cash flows from consumer products. The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. The timing of the potential consumer listing, which Sanofi said would be in the fourth quarter of 2024 or later, would be set to maximize shareholder value.
Persons: Hudson, Sanofi, drugmaker, Paul Hudson, Terence McManus, Johnson, we've, Gonzalo Fuentes, Roche, Dupixent, Ludwig Burger, Sherry Jacob, Phillips, Mark Potter, Sharon Singleton Organizations: Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer, Bayer, Polyclonals, REUTERS, Provention, Merck & Co, Thomson Locations: France, Bellevue, Lyon, Paris
☆ A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free
  + stars: | 2023-10-24 | by ( Filip De Mott | ) www.businessinsider.com   time to read: +4 min
Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. AdvertisementAdvertisementRoche's acquisition of a bowel-inflammation treatment delivered a massive windfall for presidential candidate Vivek Ramaswamy's company Roivant, the Wall Street Journal reported. But Roivant's expenses to develop the treatment, which targets an inflammatory protein called TL1A, amounted to just $15 million. And just this month, a $1.5 billion collaboration between Sanofi and Teva Pharmaceuticals was announced for more TL1A treatment. "This is a $15 billion market just in the US, and that's just in [inflammatory bowel disease," Roche chief Teresa Graham told the Journal.
Persons: Roche, Roivant, —, Vivek Ramaswamy's, Pfizer, TL1a, that's, " Roche, Teresa Graham Organizations: Wall Street Journal, Pfizer, Service, Telavant Holdings, Food and Drug Administration, Roivant, Prometheus Biosciences, Merck, Sanofi, Teva Pharmaceuticals, pharma Locations: Roivant, Japan
☆ Roche buys Roivant's bowel disease drug for $7.1 billion
  + stars: | 2023-10-23 | by ( John Revill Ludwig Burger | John Revill | Ludwig Burger | ) www.reuters.com   time to read: +2 min
New Roche CEO Thomas Schinecker is keen to restore Roche's battered drug development record after major late-stage trial setbacks in the areas of Alzheimer's and cancer immunotherapy last year. The acquired drug, against inflammatory bowel disease such as ulcerative colitis and Crohn's disease, belongs to a class of new treatments known as anti-TL1A antibodies which has attracted major deal activity in the pharma industry. Merck & Co (MRK.N) in April agreed to buy anti-TL1A antibody developer Prometheus Biosciences for $10.8 billion. Inflammatory bowel disease is a group of chronic gastrointestinal disorders with almost 8 million people diagnosed worldwide and 80% of all individuals not experiencing lasting remission, Roche said. "We strongly believe this novel TL1A directed antibody has the transformational potential to make a significant difference for patients living with inflammatory bowel disease and potentially other diseases," said Roche CEO Schinecker.
Persons: drugmaker Roche, Arnd, New Roche, Thomas Schinecker, Schinecker, Roche, John Revill, Ludwig Burger, Friederike Heine, Jason Neely Organizations: REUTERS, Roivant Holdings, Pfizer Inc, pharma, Sanofi, Merck & Co, Prometheus Biosciences, Thomson Locations: Basel, Switzerland, ZURICH, FRANKFURT, Swiss, U.S, Japan, Zurich, Frankfurt
☆ Roivant, Pfizer team up on inflammatory disease drug
  + stars: | 2022-12-01 | by ( Bhanvi Satija Khushi Mandowara | Bhanvi Satija | Khushi Mandowara | ) www.reuters.com   time to read: +2 min
Dec 1 (Reuters) - Biotech firm Roivant Sciences (ROIV.O) on Thursday launched a company with Pfizer Inc (PFE.N) focused on an experimental bowel disease treatment, as the drugmakers seek to tap into a multibillion dollar market. The drug, RVT-3101, was originally developed by Pfizer, which will hold a 25% stake in the new business, with Roivant holding the majority interest. SVB Securities analyst David Risinger says the deal shows how Pfizer is prioritizing research spending for its oral ulcerative colitis drug, etrasimod, which holds a near-term blockbuster opportunity. RVT-3101 could represent a nearly $15 billion commercial opportunity in the United States for Roivant as a treatment for both ulcerative colitis and Crohn’s disease, said Risinger. Pfizer has also licensed its inflammatory autoimmune disease drug brepocitinib to Roivant in exchange for a 25% stake in another jointly held company called Priovant.
0 next >>
Total: 5